TargetMol

Tilarginine

Product Code:
 
TAR-T26277
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T26277-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26277-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26277-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Tilarginine is a nitric oxide synthetase competitive inhibitor.
CAS:
17035-90-4
Formula:
C7H16N4O2
Molecular Weight:
188.231
Purity:
0.98
SMILES:
CNC(=N)NCCC[C@H](N)C(O)=O

References

1. Firger J. Nitric Oxide Inhibitors Hit Target for Triple-Negative Breast Cancer. J Natl Cancer Inst. 2015 Aug 4;107(8). pii: djv235. doi: 10.1093/jnci/djv235. Print 2015 Aug. PubMed PMID: 26243205; PubMed Central PMCID: PMC4609569. 2. Sand CA, Hobbs AJ. The nuances of NO synthase regulation in sepsis: Could targeting BH4 be the answer? Vascul Pharmacol. 2016 Feb;77:35-7. doi: 10.1016/j.vph.2015.10.008. Epub 2015 Nov 7. Review. PubMed PMID: 26556765. 3. Howes LG, Brillante DG. Expert opinion on tilarginine in the treatment of shock. Expert Opin Investig Drugs. 2008 Oct;17(10):1573-80. doi: 10.1517/13543784.17.10.1573 . Review. PubMed PMID: 18808317. 4. Bech JN, Aagaard NK, Pedersen RS, Sorensen TB, Vilstrup H, Pedersen EB. Renal effects of NO-inhibition in patients with cirrhosis vs. healthy controls: a randomized placebo-controlled crossover study. Liver Int. 2014 Feb;34(2):211-9. doi: 10.1111/liv.12233. Epub 2013 Jun 28. PubMed PMID: 23809512.